Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses
Top Cited Papers
- 8 January 2010
- journal article
- review article
- Published by Elsevier BV in Vaccine
- Vol. 28 (3), 632-649
- https://doi.org/10.1016/j.vaccine.2009.09.098
Abstract
No abstract availableThis publication has 97 references indexed in Scilit:
- Live Chimeric and Inactivated Japanese Encephalitis Virus Vaccines Differ in Their Cross-Protective Values against Murray Valley Encephalitis VirusJournal of Virology, 2009
- Domestic Pigs and Japanese Encephalitis Virus Infection, AustraliaEmerging Infectious Diseases, 2008
- Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse modelVirology, 2008
- Substitution of Wild‐Type Yellow Fever Asibi Sequences for 17D Vaccine Sequencesin ChimeriVax–Dengue 4 Does Not Enhance Infection ofAedes aegyptiMosquitoesThe Journal of Infectious Diseases, 2008
- DengueThe Lancet, 2007
- A live, attenuated recombinant West Nile virus vaccineProceedings of the National Academy of Sciences of the United States of America, 2006
- Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue virusesNature Medicine, 2004
- Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic feverNature Medicine, 2003
- Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease SeverityThe Journal of Infectious Diseases, 2000
- Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213Virus Research, 1995